Trends in CNS Drug Discovery

1. Auflage 2025
ISBN: 978-3-527-35280-7
Verlag: Wiley-VCH GmbH

Buch, Englisch, Band 2, 480 Seiten, Format (B × H): 170 mm x 244 mm

Reihe: Trends in Drug Discovery

Provides insights into the drug discovery innovations that are shaping future CNS therapies

In the vast field of neuroscience, drug discovery targeting the central nervous system (CNS) presents both extraordinary opportunities and complex challenges. Disorders such as Alzheimer's disease, schizophrenia, and epilepsy affect millions worldwide, demanding innovative therapeutic strategies. Yet understanding brain processes and overcoming the blood-brain barrier continue to pose significant hurdles for researchers and developers alike.

Trends in CNS Drug Discovery offers a comprehensive overview of the methodologies, successes, and challenges shaping this critical area of pharmaceutical research. Covering a wide range of key areas, from current therapeutic paradigms to emerging technologies, this state-of-the-art volume brings together expertise from leading scientists and drug developers who address the role of cannabinoids and psychedelics in advancing CNS therapeutics, discuss emerging modalities such as protein degraders and allosteric modulators, examine funding strategies and academic-industrial collaborations, highlight advancements in brain-penetrating cancer treatments and other high-impact areas, and more. - Explores cutting-edge methodologies, including biomarkers, animal models, and brain imaging for CNS drug discovery
- Reviews innovative therapies such as combination drugs and prodrugs for improved treatment outcomes
- Analyzes challenges in targeting diseases including Alzheimer's and schizophrenia with novel therapeutic strategies
- Includes real-world case studies demonstrating achievements and lessons in CNS drug development

A critical reference for academic researchers and industry professionals in medicinal chemistry, pharmaceutical research, and neurobiology, Trends in CNS Drug Discovery is also an ideal resource for graduate-level courses in neuroscience or pharmaceutical sciences.

Autoren/Hrsg.

Doller, Dario

Hodgetts, Kevin

Weitere Mitwirkende

Fischer, János

Klein, Christian

Childers, Wayne E.

Rotella, David P.

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Naturwissenschaften Biowissenschaften Biowissenschaften Neurobiologie, Verhaltensbiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft

Inhaltsverzeichnis

PART 1: CURRENT STATUS AND THERAPY OVERVIEW
Drug discovery in the Century of Biology
Academic vs. Industrial CNS drug discovery: An evolving relationship
The role of Venture Capital in drug discovery
Spin-off companies
The NIH role catalyzing the discovery of novel treatments
PART 2: KEY QUESTIONS FOR CONTEMPORARY CNS DRUG DISCOVERY
The end: defining CNS diseases (molecular vs phenotype)
Target selection in the treatment of CNS diseases
The use of animal models in brain drug research
Biomarkers in CNS drug discovery
PET imaging in CNS drug discovery
PART 3: PSYCHEDELIC-INSPRIRED DRUG DISCOVERY
Update on ketamine, esketamine, arketamine
Non-hallucinogenic antidepressants
Cannabinoids as therapeutics for brain disease
PART 4: UNION MAKES STRENGTH: COMBINING DRUGS TO PRODUCE NOVEL CNS THERAPEUTICS
Xanomeline-trospium for schizophrenia
Olanzapine-samidorphan
Dextromethorphan-bupropion
Levodopa prodrug
Apomorphine
PART 5: EMERGING CHEMICAL MODALITIES FOR BRAIN DISEASES
PROTACs in CNS drug discovery
Small molecule allosteric modulators
Progress using biologics drugs for CNS diseases (CGRP migraine, Anti-amyloid antibodies, MSA/PD and a-SYN antibodies)
Using mechanistic studies for CNS diseases
What is the best surrogate of brain penetration?
Brain cancer treatments (brain penetration of kinase inhibitor)
PART 6: EPILOGUE
Treating brain disease in the next decade
 

Über Autor(innen)

Dario Doller, PhD, has over 25 years of experience in pharmaceutical research, contributing to numerous clinical compounds and marketed drugs. He has authored over 100 articles and patents and is Director of Medicinal Chemistry at iNeuro Therapeutics.

Kevin J. Hodgetts, PhD, is Associate Professor of Neurology at Harvard Medical School and Head of Medicinal Chemistry and Director of the Lab for Drug Discovery in Neuroscience (LDDN) at Brigham and Women's Hospital.